These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 16145760)

  • 21. [The CARDS Study: cardiovascular primary prevention in diabetes patients using Atorvastin].
    Griebenow R
    Internist (Berl); 2005 Mar; 46(3):350-2. PubMed ID: 15696286
    [No Abstract]   [Full Text] [Related]  

  • 22. Statins and coronary artery disease--it's the clinical endpoints that count.
    Jackson G
    Br J Clin Pract; 1997; 51(1):2-3. PubMed ID: 9158261
    [No Abstract]   [Full Text] [Related]  

  • 23. [Stroke, cholesterol and statins--are there new data about stroke prevention?].
    Ferbert A
    Dtsch Med Wochenschr; 2001 Jun; 126(22):664-70. PubMed ID: 11450627
    [No Abstract]   [Full Text] [Related]  

  • 24. Co-administration of ezetimibe and simvastatin in acute myocardial infarction.
    Chenot F; Montant PF; Marcovitch O; Blaimont M; de Meester A; Descamps OS
    Eur J Clin Invest; 2007 May; 37(5):357-63. PubMed ID: 17461981
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The need for wider and appropriate utilization of aspirin and statins in the treatment and prevention of cardiovascular disease.
    Hennekens CH; Schneider WR
    Expert Rev Cardiovasc Ther; 2008 Jan; 6(1):95-107. PubMed ID: 18095910
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MRC/BHF Heart Protection Study.
    Wald N; Law M;
    Lancet; 2002 Nov; 360(9347):1781; author reply 1783-4. PubMed ID: 12480448
    [No Abstract]   [Full Text] [Related]  

  • 27. Intensive lipid lowering in patients with rheumatoid arthritis and previous myocardial infarction: an explorative analysis from the incremental decrease in endpoints through aggressive lipid lowering (IDEAL) trial.
    Semb AG; Holme I; Kvien TK; Pedersen TR
    Rheumatology (Oxford); 2011 Feb; 50(2):324-9. PubMed ID: 20884656
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Coronary heart disease: grave deficiencies in secondary prevention. Almost no one is concerned with blood lipids].
    Arnheim K
    MMW Fortschr Med; 2000 Jun; 142(24):18. PubMed ID: 10895577
    [No Abstract]   [Full Text] [Related]  

  • 29. Natural statins and stroke risk.
    Furberg CD
    Circulation; 1999 Jan; 99(2):185-8. PubMed ID: 9892578
    [No Abstract]   [Full Text] [Related]  

  • 30. Updated guidelines support even lower cholesterol levels for at-risk patients.
    Levenson D
    Rep Med Guidel Outcomes Res; 2004 Aug; 15(15):1, 6-7. PubMed ID: 15320342
    [No Abstract]   [Full Text] [Related]  

  • 31. [The cholesterol hypothesis has been proved true at last].
    Huttunen J
    Duodecim; 1995; 111(5):385-6. PubMed ID: 8674438
    [No Abstract]   [Full Text] [Related]  

  • 32. Simvastatin for secondary prevention of all-cause mortality and major coronary events in patients with mild chronic renal insufficiency.
    Chonchol M; Cook T; Kjekshus J; Pedersen TR; Lindenfeld J
    Am J Kidney Dis; 2007 Mar; 49(3):373-82. PubMed ID: 17336698
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A comparison of efficacy and safety of an ezetimibe/simvastatin combination compared with other intensified lipid-lowering treatment strategies in diabetic patients with symptomatic cardiovascular disease.
    Rosen JB; Jimenez JG; Pirags V; Vides H; Hanson ME; Massaad R; McPeters G; Brudi P; Triscari J
    Diab Vasc Dis Res; 2013 May; 10(3):277-86. PubMed ID: 23288881
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Dual cholesterol inhibition. More high risk patients achieve LDL cholesterol values below 100 mg/dl].
    MMW Fortschr Med; 2008 Jun; 150(23):39. PubMed ID: 18575369
    [No Abstract]   [Full Text] [Related]  

  • 35. [The other face of statins].
    Kaletha K; Chodorowski Z; Sein Anand J; Szydłowska M; Rybakowska I; Nagel-Starczynowska G
    Przegl Lek; 2002; 59(4-5):364-6. PubMed ID: 12184008
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Labeling changes for cholesterol drug.
    FDA Consum; 2003; 37(4):8. PubMed ID: 12971338
    [No Abstract]   [Full Text] [Related]  

  • 37. Risk factors for a major coronary event after myocardial infarction in the Scandinavian Simvastatin Survival Study (4S). Impact of predicted risk on the benefit of cholesterol-lowering treatment.
    Wilhelmsen L; Pyörälä K; Wedel H; Cook T; Pedersen T; Kjekshus J
    Eur Heart J; 2001 Jul; 22(13):1119-27. PubMed ID: 11428852
    [TBL] [Abstract][Full Text] [Related]  

  • 38. I've read that, because I have type 2 diabetes, I should take a statin even though my cholesterol levels are normal. Is this true?
    Johns Hopkins Med Lett Health After 50; 2005 May; 17(3):8. PubMed ID: 15841555
    [No Abstract]   [Full Text] [Related]  

  • 39. ACE inhibitors reduce heart-related death in type 2 diabetics.
    Health News; 2004 Oct; 10(10):15. PubMed ID: 15584126
    [No Abstract]   [Full Text] [Related]  

  • 40. New American College of Cardiology and American Heart Association cholesterol treatment guidelines: subjects with Type 2 diabetes are under treated with high-intensity statins.
    Tripolt NJ; Sourij H
    Diabet Med; 2014 Jul; 31(7):879-80. PubMed ID: 24612178
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.